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Summary Cellular DNA was analysed by flow cytometry in fine needle aspirates (FNA) from both benign
and malignant breast lesions in order to determine the feasibility of flow cytometric analysis. In 22 of 26
(84%) benign and 69 of 74 (93%) malignant aspirates, sufficient cells were present to produce good quality
DNA histograms. DNA in all 22 benign lesions was diploid. In contrast, of the 69 cancers with sufficient cells
for analysis, 40.6% had a diploid DNA content alone, whilst 59.4% had an additional DNA aneuploid line.
These results indicate that the majority of FNAs provide sufficient material for flow cytometric analysis of
DNA profiles. Such aspirates taken in a sequential manner may also prove to be an ideal method of studying
tumour response to therapy.
Fine needle aspiration (FNA) cytology is a valuable
technique by which to confirm the diagnosis of breast cancer
(Dixon et al., 1984). Microscopic identification of the
morphological features of malignancy does, however,
demand considerable skill from the pathologist. The recent
development of flow cytometry provides both a rapid and
objective method of analysing specific cellular structures,
such as DNA, using specific fluorochromes. Such studies
have shown an abnormal nuclear DNA content to be a
useful marker of malignancy (Barlogie et al., 1983) - the
incidence of DNA abnormality in breast cancer having been
reported to be between 44 and 90% (Kute et al., 1981;
Olszewski et al., 1981). The DNA content of individual
breast cancer cells may also be related to tumour behaviour,
there being a number of reports showing improved survival
associated with normal or near normal DNA content in
colon (Wolley et al., 1982), prostate (Fordham et al., 1986),
and breast (Auer et al., 1980; Baildam et al., 1987;
Kallioniemi et al., 1987). Such a rapid and precise method of
measuring tumour cell DNA content may therefore be of
both diagnostic and prognostic value.
Although fresh, frozen, and paraffin-embedded breast
tumour tissue have all proved suitable for flow cytometric
analysis, material obtained by fine needle aspiration of the
breast has not yet been systematically studied. Since the role
of FNA cytology in the diagnosis of breast cancer in this
unit is established (Dixon et al., 1984), this study was carried
out to determine the feasibility of carrying out DNA analysis
of FNA's by flow cytometry.
Patients and methods
Fine needle aspirates were obtained from 100 patients
attending the Diagnostic Breast Clinic, University
Department of Clinical Surgery at the Royal Infirmary of
Edinburgh, between January 1986 and November 1986.
Most aspirates were performed by the same clinician (PAL).
Of these women, 74 were diagnosed as having breast
cancer, all patients under the age of 70 having histological
examination of the tumour following biopsy of tissue for
oestrogen receptor analysis. Diagnosis of cancer in women
over 70 was mostly confirmed by cytology, the majority of
patients being treated without any form of surgery. Twenty
six women were diagnosed as having benign breast disease
either by histology of a subsequent biopsy, or in the case of
solid lesions in patients under the age of 35, by cytology of
the fine needle aspirate which, when displaying plentiful
normal epithelial elements in addition to bare nuclei, was
diagnostic of a fibroadenoma. (Lever et al., 1985).
In a limited number of cases, sequential aspirates have
been taken during systemic treatment in an attempt to
identify early cellular changes taking place, and hence
possibly predict clinical response to treatment at an early
stage.
The method of aspiration has been described previously
(Zajicek, 1965), but briefly aspirates were obtained using a
23 gauge needle attached to a 10ml syringe. The lesion was
localised with the needle tip and negative pressure applied.
Using a gentle pumping action, material was aspirated into
the needle, the pressure was released, and the needle
withdrawn.
Material was expelled onto 4 dry glass slides and smears
prepared: 2 were air dried for subsequent May Grunwald
Giemsa staining, and 2 were fixed in alcohol for
Papanicoulaou staining. All slides were examined by two
pathologists and categorised as either malignant, suspicious,
benign or acellular (Dixon et al., 1984). A further drop of
aspirated material was taken for immunohistochemical assay
of the oestrogen receptor. The remainder of the aspirate,
which was to be used for flow cytometric analysis, was
expelled into 200Il of citrated buffer, rapidly frozen on dry
ice, and stored at -40°C until analysed (Vindel0v et al.,
1983a).
Flow cytometric DNA analysis
Frozen whole cell suspensions were thawed in a water bath
at 370C before preparing and staining the nuclei as described
by Vindel0v et al. (1983b) with minor modifications.
Cell suspensions (100ll) were digested by mixing with
trypsin (0.003%, 450,u1) and leaving at room temperature
for 10mins. Trypsin inhibitor (0.05% w/v) and RNAse
(0.01%w/v) in a final volume of 375,p1 were then added
and then left for a further 10mins. Finally, the cells were
stained, on ice, with propidium iodide (416pgml-1) and
spermine tetrahydrochloride (1.16mgml-1) in a final volume
of 250p1. Samples were passed through a gauge 23 needle
prior to analysis.
Trout blood obtained from a caudal vein and chicken
blood from a wing vein were added as internal standards in
order to calculate the DNA index (DI), their nucleated red
cells containing approximately 80% and 35% of normal
human diploid DNA respectively (Vindel0v et al., 1983c).
Cellular DNA content was measured using an EPICS C
flow cytometer (Coulter Electronics Ltd, Hialeah, Florida).
The nuclei were excited by a 250mW beam of 488 nm light
from a 5 watt argon ion laser. Red fluorescence emission
was measured using a 515 laser blocking filter and 570
barrier filter. The resulting DNA histogram was generated
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by counting at least 10,000 sample nuclei at a speed of
<50sec-.
Results
Of the 100 samples studied, 22 of 26 (84%) benign and 69 of
74 (93%) malignant aspirates contained sufficient cells to
accumulate a good quality DNA histogram of 10,000 sample
cells with minimal debris. Of the 9 cases with insufficient
cells for analysis, smears taken for cytology in 3 (2 cancers
and 1 benign) were also acellular. In the remaining 6
samples, cytological examination revealed the presence of
cellular material, but only in quantities sufficient for
diagnostic purposes and estrogen receptor status, both of
which were given priority.
Full peak coefficients of variation of GO/I peaks, as
calculated using the Coulter statistics software, had a range
of 2.00 to 6.25 (mean=3.75).
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Figure 1 DNA histogram obtained from a fine needle aspirate
of a fibroadenoma. Peaks 1 and 2 represent nucleated chicken
and trout red blood cells respectively. Peak 3 represents sample
nuclei in the GO/I phase with a DI of 0.98, whilst peak 4
represents the benign cells in the G2 or M phase of the cell cycle.
Benign lesions
Sufficient cells were obtained in FNAs from 22 benign
lesions comprising of fibroadenomas(4), fibrosis(4), fat
necrosis(l), mammary dysplasia(l), sclerosing papilloma(l),
fibrocystic disease(l) and benign breast disease(l). Further
histology was not carried out for the remaining 9. In each
case, flow cytometric analysis of the aspirate revealed a
single DNA peak representing GO/I cells (Figure 1), the
mean DI being 0.99+0.06. A normal DI range was defined
as 0.9-1.1. In 16 cases, G2/M cells were also identified as
small peaks with a DI twice that of the GO/I.
Malignant lesions
The 69 cancers with sufficient cells for analysis were derived
from invasive carcinomas. All contained a population of cells
with a normal DNA content (DI=0.99+0.06). In 28 cases,
no other population was identified and these cancers were
therefore defined as 'DNA diploid'. However, an additional
and abnormal stemline was detected in 41 cases [59.4%].
Most of these DNA aneuploid tumours [35] contained a
single abnormal cell population, although 6 were multiclonal
(Figure 2). The distribution of DI values from the 47
abnormal stemlines is shown in Figure 3, the majority (39)
having a DI of between 1.45 and 2.0 (mean= 1.74+0.33).
Figure 4a, b represents DNA histograms from a single
patient before and after treatment with Mitoxantrone, and
show a reduction in the relative proportion of cells with an
abnormally high DNA content.
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Figure 2 DNA histogram of a DNA aneuploid invasive ductal
carcinoma. Three distinct populations (3, 4 and 5) can be
identified in the sample, having DIs of 0.95, 1.45, and 1.63
respectively. Smaller peaks (6 and 7) presumably correspond to
the fraction of cells in the G2/M phase of peaks 4 and 5
respectively. Internal standards are again represented by peaks 1
and 2.
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Discussion
Flow cytometric analysis of breast tumours is potentially a
valuable technique in that it can provide useful data on the
cellular characteristics of tumours. For example, we have
shown that it is possible to obtain accurate DNA histograms
of tumour cells. Whilst the value of such measurements is
controversial, some studies report significant survival
advantages for patients with diploid as opposed to aneuploid
tumours (Auer et al., 1980; Baildam et al., 1987; Kallioniemi
et al., 1987). Others indicate that ploidy per se is unlikely to
be of prognostic value (Dowle et al., 1987; Owainati et al.,
1987), or is only an independent prognostic variable in
postmenopausal patients (Cornelisse et al., 1987).
To date, most flow cytometric DNA analysis has been
carried out using excised tumour material. This present study
therefore represents the first report on the use of cellular
preparations from routine diagnostic breast tumour FNA's
for flow cytometric analysis.
The results indicate that, in over 90% of malignant
tumours and 80% of benign lesions, fine needle aspirates
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Figure 3 Distribution of calculated DI values for 47 abnormal
cell lines identified in 41 DNA aneuploid breast tumours.
contain sufficient cells to provide, in addition to diagnostic
cytopathology, good quality flow cytometric DNA histograms.
Furthermore, the majority of samples contained minimal
amounts of debris material, allowing the identification of
any small sub-populations of cells.
All aspirates from tumours subsequently shown by routine
pathology to be benign contained a single population of
GO/GI cells, as did 40% of tumours confirmed as malignant;
the remaining 60% of FNAs from cancers contained at least
one DNA aneuploid line. These results would fall midway
within the, albeit large, range of values reported by others
(Kute et al., 1981; Olszewski et al., 1981) using samples
obtained from excised tumours. This suggests that the
cellular composition of FNAs is largely representative of the
tumour and reflects results obtained using the larger cell
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Figure 4 DNA histograms (a) before and (b) after 4 weeks
mitoxantrone treatment. Prior to treatment, analysis showed two
populations of cells (3 and 4) with DI values of 0.96 and 1.78
respectively (internal standards are represented by peaks 1 and
2). After treatment, there has been a dramatic reduction in the
relative proportion of cells with an abnormally high DNA
content. Cytology confirmed the presence of cancer cells in both
cases.
numbers available from excised biopsies (the possibility that
minor cell populations may be missed cannot be excluded
but is a criticism of any method involving tumour sampling).
Furthermore, the coefficients of variation obtained are
similar to those reported for the analysis of cellular
suspensions prepared from both surgical and paraffin-
embedded material.
Additionally, DNA analysis can be carried out on surplus
cells remaining in the FNA after material has been taken for
diagnostic purposes. Since FNA cytology is now accepted as
being reliable in the hands of an experienced operator
(Dixon et al., 1984), it is more widely employed for routine
diagnosis. In certain cases, flow cytometric DNA analysis of
FNA material may provide additional diagnostic informa-
tion in that although DNA aneuploid cells have been detected
in benign lesions of the breast (Cornelisse et al., 1983;
Uccelli et al., 1986) and other tissues (Danova et al., 1987;
Jarvis et al., 1987; Joensuu et al., 1986), the incidence is
relatively low. The presence of a distinct population of DNA
aneuploid cells may therefore be indicitive of malignancy.
The presence of diploid cells alone can not however facilitate
diagnosis, as these may be both non-malignant and
malignant; although with the development of specific tumour
markers it may subsequently be possible to distinguish
between these diploid cell populations.
Whilst the results obtained from FNAs are compatible
with those obtained from more conventional analysis of
excised tumour tissue, the combination of flow cytometry
and FNA cytology has more extensive applications. Thus,
although not all patients are suitable for tumour biopsy,
FNA cytology can be performed in most cases. For example,
surgery may not be appropriate in the older patient,
although information on cellular characteristics of the
tumour might provide useful information on the nature of
systemic therapy to be employed. Similarly, it would be
possible to obtain an FNA on small or surgically inoperable
metastatic lesions and again analysis could yield information
useful to the management of the patient.
The simplicity and relatively non-invasiveness of FNA
cytology not only permits the study of individual tumour
cells prior to treatment, but also sequential sampling during
therapy. Flow cytometric analysis may therefore allow direct
monitoring of cellular changes occurring within a tumour
during treatment, and we are currently exploring this
approach in the management of large but operable breast
tumours treated with initial systemic therapy (Forrest et al.,
1986). The ability to assess early response may allow
appropriate drugs to be instituted sooner, and inappropriate
ones to be promptly discontinued. In view of the toxicity of
some chemotherapeutic agents, the latter may be particularly
important.
To conclude, in the hands of an experienced aspirator,
cellular material from FNAs of breast tumours provide
suitable material for flow cytometric analysis. The com-
bination of these techniques has great potential in terms of
characterising the cellular properties of tumours without the
need for surgical removal of tissue.
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